Connor Clark & Lunn Investment Management Ltd. Acquires 242,249 Shares of Savara Inc (NASDAQ:SVRA)

Connor Clark & Lunn Investment Management Ltd. grew its stake in shares of Savara Inc (NASDAQ:SVRA - Free Report) by 54.0% in the third quarter, according to its most recent filing with the SEC. The fund owned 690,609 shares of the company's stock after acquiring an additional 242,249 shares during the period. Connor Clark & Lunn Investment Management Ltd. owned about 0.42% of Savara worth $2,928,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds also recently modified their holdings of the company. Frazier Life Sciences Management L.P. grew its position in Savara by 103.9% during the second quarter. Frazier Life Sciences Management L.P. now owns 8,157,385 shares of the company's stock valued at $32,874,000 after purchasing an additional 4,157,385 shares in the last quarter. Jennison Associates LLC raised its stake in shares of Savara by 17.5% in the 3rd quarter. Jennison Associates LLC now owns 6,732,776 shares of the company's stock valued at $28,547,000 after acquiring an additional 1,001,296 shares in the last quarter. Vanguard Group Inc. lifted its holdings in Savara by 2.5% in the 1st quarter. Vanguard Group Inc. now owns 6,063,620 shares of the company's stock worth $30,197,000 after purchasing an additional 148,673 shares during the last quarter. Nantahala Capital Management LLC grew its stake in Savara by 198.2% in the 2nd quarter. Nantahala Capital Management LLC now owns 5,180,951 shares of the company's stock valued at $20,879,000 after buying an additional 3,443,541 shares during the last quarter. Finally, Farallon Capital Management LLC boosted its holdings in Savara by 90.5% during the second quarter. Farallon Capital Management LLC now owns 4,560,000 shares of the company's stock valued at $18,377,000 after acquiring an additional 2,165,701 shares during the period. 87.93% of the stock is owned by institutional investors and hedge funds.

Savara Trading Up 1.5 %

SVRA stock traded up $0.05 during midday trading on Monday, reaching $3.41. The company's stock had a trading volume of 908,687 shares, compared to its average volume of 1,260,057. The business's 50-day simple moving average is $3.75 and its 200-day simple moving average is $4.11. The company has a quick ratio of 17.70, a current ratio of 17.70 and a debt-to-equity ratio of 0.13. Savara Inc has a 52 week low of $2.82 and a 52 week high of $5.70. The stock has a market cap of $585.22 million, a PE ratio of -7.93 and a beta of 1.02.

Savara (NASDAQ:SVRA - Get Free Report) last released its quarterly earnings data on Tuesday, November 12th. The company reported ($0.11) earnings per share for the quarter, hitting the consensus estimate of ($0.11). As a group, sell-side analysts expect that Savara Inc will post -0.45 EPS for the current year.

Insider Activity at Savara

In other Savara news, Director Joseph S. Mccracken bought 20,000 shares of the firm's stock in a transaction that occurred on Tuesday, November 19th. The stock was acquired at an average price of $2.95 per share, with a total value of $59,000.00. Following the completion of the transaction, the director now owns 210,837 shares in the company, valued at approximately $621,969.15. This trade represents a 10.48 % increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. 5.13% of the stock is currently owned by insiders.

Wall Street Analysts Forecast Growth

SVRA has been the topic of several research reports. Evercore ISI restated an "in-line" rating and set a $5.00 price target (down from $7.00) on shares of Savara in a research note on Wednesday, November 13th. JMP Securities reissued a "market outperform" rating and set a $9.00 price objective on shares of Savara in a report on Tuesday, October 1st. Finally, HC Wainwright cut their target price on Savara from $10.00 to $6.00 and set a "buy" rating for the company in a research note on Wednesday, November 13th. One investment analyst has rated the stock with a hold rating and five have issued a buy rating to the company's stock. Based on data from MarketBeat, Savara has a consensus rating of "Moderate Buy" and a consensus price target of $10.17.

Savara Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.